Cosentyx unoready 300 MG pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F5Z63
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $281,333
Award facts
- Contract value 100% obligated
- $281,333.24 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $281,333.24 to AmerisourceBergen Drug Corp for the supply of Cosentyx (secukinumab) 300 mg pen auto-injectors in 2 ml formulations. This is a firm fixed-price, non-set-aside competitive award with an ultimate completion date of January 26, 2026. The delivery order was executed on January 23, 2026, and performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Cosentyx is a biologic medication used to treat various inflammatory conditions including psoriasis, psoriatic arthritis, and ankylosing spondylitis, indicating this procurement supports the pharmaceutical needs of military healthcare systems.
This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the delivery of a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and medical devices. The IDC structure allows AmerisourceBergen to efficiently fulfill critical pharmaceutical requirements across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Quick answers
Who was awarded contract SPE2DR26F5Z63?
SPE2DR26F5Z63 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 23, 2026.
How much is contract SPE2DR26F5Z63 worth?
The government has obligated $281,333 on SPE2DR26F5Z63.
Is contract SPE2DR26F5Z63 an order under another contract?
Yes. SPE2DR26F5Z63 is a delivery order under SPE2DR25D3101, an indefinite delivery contract.
Was contract SPE2DR26F5Z63 competed?
The extent of competition for SPE2DR26F5Z63 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award